Single-blind, placebo phase-in trial of two escalating doses of selegiline in the chronic fatigue syndrome

Neuropsychobiology

Volumn 37, Issue 3, 1998, Pages 150-154

  Natelson, Benjamin H ^a   Cheu, Joseph ^a   Hill, Nancy ^a   Bergen, Michael ^a   Korn, Leo ^a   Denny, Thomas ^b   Dahl, Kristina ^a  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY   (United States)

Author keywords

Chronic fatigue syndrome; Monoamine oxidase inhibitor; Selegiline

Indexed keywords

PHENELZINE; PLACEBO; SELEGILINE;

ANXIETY; ARTICLE; CHRONIC FATIGUE SYNDROME; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; MOOD; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; QUESTIONNAIRE; SEXUALITY; SINGLE BLIND PROCEDURE; TENSION;

ACTIVITIES OF DAILY LIVING; AFFECT; DRUG ADMINISTRATION SCHEDULE; FATIGUE SYNDROME, CHRONIC; HUMANS; MONOAMINE OXIDASE INHIBITORS; NEUROPROTECTIVE AGENTS; SELEGILINE;

EID: 0031918979     PISSN: 0302282X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000026494     Document Type: Article

References (28)

1. Holmes GP, Kaplan JE, Gantz NM, et al: Chronic fatigue syndrome: A working case definition. Ann Intern Med 1988;108:387-389.
2. Komaroff AL, Buchwald D: Symptoms and signs of chronic fatigue syndrome. Rev Infect Dis 1991;13:S8-S11.
3. Fulcher KY. White PD: Randomised controlled trial of graded exercise in patients with the chronic fatigue syndrome. Br Med J 1997; 314:1647-1652.
4. Deale A, Chalder T, Marks I, Wessely S: Cognitive behavior therapy for chronic fatigue syndrome: A randomized controlled trial. Am J Psychiatry 1997;154:408-414.
5. Natelson BH, Cheu J, Pareja J, Ellis SP, Policastro T, Findley TW: Randomized, double blind, controlled placebo-phase in trial of low dose phenelzine in the chronic fatigue syndrome. Psychopharmacology 1996; 124:226-230.
6. Mallinger AG, Smith E: Pharmacokinetics of monoamine oxidase inhibitors. Psychopharmacol Bull 1991;27:493-504.
7. Stoll S, Hafner U, Pohl O, Müller WE: Agerelated memory decline and longevity under treatment with selegiline. Life Sci 1994;55: 2155-2163.
8. DeLuca J, Johnson SK, Beldowicz D, Natelson BH: Neuropsychological impairments in chronic fatigue syndrome, multiple sclerosis, and depression. J Neurol Neurosurg Psychiatry 1995;58:38-43.
9. Fukuda K, Straus SE, Hickie I, et al: The chronic fatigue syndrome: A comprehensive approach to its definition and study. Ann Intern Med 1994;121:953-959.
10. Marcus S, Robins LN, Bucholz K: Quick Diagnostic Interview Schedule 3R version 1. St Louis, Washington University School of Medicine, 1990.
11. Radloff LS: The CES-D scale: A self-report depression scale for research in the general population. Appl Psychol Measurement 1977;1: 385-401.
12. Schulberg H, Saul M, McClelland M, Ganguli M, Christy W, Frank R: Assessment of depression in primary medical and psychiatric practices. Arch Gen Psychiatry 1985;42:1164-1170.
13. Jette AM, Davies AR, Clearly PD, et al: The functional status questionnaire: Reliability and validity when used in primary care. J Gen Intern Med 1988;1:143-149.
14. McNair DM, Lorr M. Droppleman LF: Profile of Mood States: Manual. San Diego, Educational and Industrial Testing Service, 1971.
15. Pepper CM, Krupp LB, Friedberg F, Doscher C, Coyle PK: A comparison of neuropsychiatrie characteristics in chronic fatigue syndrome, multiple sclerosis, and major depression. J Neuropsychiatry Clin Neurosci 1993;5:200-205.
16. Efron B, Tibshirani T: Permutation tests; in An Introduction to the Bootstrap (anonymous). New York, Chapman & Hall, 1993, pp 202-219.
17. 12U), in chronic fatigue syndrome. Clin Infect Dis 1994;18(suppl 1):S88-S95.
18. Lloyd AR, Hickie I, Brockman A, et al: Immunologic and psychologic therapy for patients with chronic fatigue syndrome: A double-blind, placebo-controlled trial. Am J Med 1993;94: 197-203.
19. Vercoulen JHMM, Swanink CMA, Zitman FG, et al: Randomised, double-blind, placebo-controlled study of fluoxetine in chronic fatigue syndrome. Lancet 1996;347:858-861.
20. Cleare AJ, Wessely SC: Fluoxetine and chronic fatigue syndrome. Lancet 1996;347:1770.
21. Natelson BH, Johnson SK, DeLuca J, et al: Reducing heterogeneity in chronic fatigue syndrome: A comparison with depression and multiple sclerosis. Clin Infect Dis 1995;21: 1204-1210.
22. Cox IM, Campbell MJ, Dowson D: Red blood cell magnesium and chronic fatigue syndrome. Lancet 1991;337:757-760.
23. Behan PO. Behan WMH: Essential fatty acids in the treatment of postviral fatigue syndrome; in Horrobin DF (ed): Omega 6 Essential Fatty Acids: Pathophysiology and Role in Clinical Medicine. New York, Wiley-Liss, 1990, pp 275-282.
24. DuBois RE: Gamma globulin therapy for chronic mononucleosis syndrome. AIDS Res 1986;2(suppl 1):S191-S195.
25. Plioplys AV, Plioplys S: Amantadine and L-carnitine treatment of chronic fatigue syndrome. Neuropsychobiology 1997;35:16-23.
26. Hana I, Vrubel J, Pekarek J, Cech K: The influence of age on transfer factor treatment of cellular immunodeficiency, chronic fatigue syndrome and/or chronic viral infections. Biotherapy 1996;9:91-95.
27. Brook MG, Bannister BA, Weir WRC: Interferon-α therapy for patients with chronic fatigue syndrome. J Infect Dis 1993;168:791-792.
28. White PD, Cleary KJ: An open study of the efficacy and adverse effects of moclobemide in patients with the chronic fatigue syndrome. Int Clin Psychopharmacol 1997;12:47-52.